Heterozygosity for the thiopurine methyltransferase *3A allele in an acute non-lymphoblastic leukaemia patient with delayed marrow regeneration following H-DAT chemotherapy [6]

British Journal of Haematology

Volumn 112, Issue 4, 2001, Pages 1089-

  Standen, Graham R ^a   Wood, Nigel A P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

ANLL; Thioguanine; TPMT

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ALLELE; CASE REPORT; CAUCASIAN; GENE MUTATION; HEMATOPOIESIS; HETEROZYGOSITY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; REMISSION; SEQUENCE ANALYSIS;

ADULT; ALLELES; ANTINEOPLASTIC AGENTS; HETEROZYGOTE; HUMANS; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; METHYLTRANSFERASES; MUTATION; THIOGUANINE;

EID: 0035044441     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02622-6.x     Document Type: Letter

References (4)

1. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azothioprine
2. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations
3. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
4. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance